What is GHRP-2? A plain-English explainer
A lab-made, six-amino-acid peptide belonging to the growth-hormone-releasing-peptide family.
GHRP-2 is a synthetic peptide — a short chain of just 6 amino acids, known as a hexapeptide, belonging to the growth-hormone-releasing-peptide (GHRP) family. It is sold and studied in the United States as a research chemical; a related formulation is approved in Japan solely as a diagnostic tool.
That one paragraph is the whole definition. The rest of this page unpacks it at two levels — plain English, then a little deeper — and shows how the reconstitution math works, because GHRP-2 ships as a dried powder that has to be mixed and measured before anything else.
GHRP-2 in plain English
GHRP-2 is only 6 amino acids long — a short peptide that chemists specifically call a hexapeptide, “hexa” meaning six.
Unlike a peptide such as BPC-157 or AOD-9604, which are fragments of larger naturally occurring proteins, GHRP-2 is not cut from a bigger molecule. It was designed and synthesised from scratch as a member of a family of compounds called growth-hormone-releasing peptides, studied for their relationship to growth-hormone secretion from the pituitary gland.
It usually arrives as a small glass vial of white powder. The powder is the peptide with the water removed (freeze-dried, or “lyophilised”) so it stays stable in storage. On its own the powder can’t be measured into a syringe — there’s no volume to draw. That’s why the next step, reconstitution, exists.
The science, a little deeper
A few specifics that the plain-English version glosses over:
- It’s a defined sequence, not a mixture. GHRP-2 has a single, known 6-amino-acid sequence (D-Ala-D-2Nal-Ala-Trp-D-Phe-Lys-NH₂). That’s what makes it a peptide in the chemical sense rather than an extract.
- Its pharmaceutical name is pralmorelin. Under that name, a manufactured version has been approved in Japan since 2004 — but only as an injectable diagnostic agent, used in a clinical test that measures how much growth hormone the pituitary gland releases. It is not approved there, or anywhere, for routine or ongoing use.
- It’s supplied lyophilised. Removing the water gives the powder a long shelf life; adding a measured liquid back (reconstitution) is what turns it into an injectable solution with a known strength.
- “Research chemical” is a regulatory status, not a marketing word. In the United States, GHRP-2 has not been approved as a drug for any indication. Much of what’s published about it outside its Japanese diagnostic-test use is preclinical or limited clinical research, and this page makes no claim about what it does in people.
If you want the classification in one line: GHRP-2 is a synthetic research hexapeptide, 6 amino acids, a member of the growth-hormone-releasing-peptide family, supplied as a freeze-dried powder for reconstitution.
How reconstitution works for GHRP-2
Reconstitution is just dissolving the powder in a known volume of liquid so you have a concentration — milligrams of peptide per millilitre of solution. Once the concentration is fixed, the volume you draw for any target dose is simple arithmetic:
- Concentration = vial amount (mg) ÷ diluent volume (mL)
- Draw volume = target dose ÷ concentration
- Syringe units = draw volume (mL) × the units-per-mL of your syringe
The numbers all come from your own vial label and your prescription — the peptide amount printed on the vial, the volume of bacteriostatic water you add, and the dose you were told to use. The separate Amidra web calculator runs exactly those three steps and shows the formula at each one, so you can check it by hand. It never fills in a dose for you.
What Amidra does — and doesn’t — do here
Amidra is a tracking and education tool. It converts the values you enter and helps you keep a protocol organised; it does not recommend a dose, a compound, or a schedule, and it takes no position on whether anyone should use GHRP-2. Those decisions belong with a qualified healthcare professional. The information above is definitional — what the compound is — not medical advice.